MELANOMA

This early-phase trial tests a custom-made RNA vaccine designed to help the immune system recognize and attack tumors in people with advanced melanoma or soft tissue sarcoma whose cancer has worsened despite standard immunotherapy. Up to 18 adults will receive three doses of the …

This early-stage trial tests a new treatment called IDOV-Immune, a virus designed to infect and destroy cancer cells while also boosting the immune system. It is for adults with advanced solid tumors (like colorectal, lung, or breast cancer) that have not responded to standard tr…

This study tests an experimental drug called N17350 in adults with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumor lesions every two weeks for up to 12 weeks. Researchers want to see if it can shrink or stop tumor gro…

This study tests a new drug called BI-1808, alone or with another drug (pembrolizumab), in people with advanced cancers that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how well the drug works. About 176 adults with s…

This study tests whether adding low-dose radiation to the liver can help immunotherapy work better for people with melanoma or non-small cell lung cancer that has spread to the liver. About 21 participants will receive standard immunotherapy plus liver radiation. The goal is to s…

This study tests atezolizumab, a drug already approved for some cancers, in people with rare cancers that have high tumor mutational burden (TMB), high microsatellite instability (MSI), or a specific DNA repair defect (CMMRD). About 30 adults, teens, and children will receive the…

This study tests whether adding hydroxychloroquine (a malaria drug) to standard immunotherapy (nivolumab with or without ipilimumab) is safe and works better for people with advanced melanoma that has spread. About 94 adults with stage III or IV melanoma will take part. The goal …

This program provides early access to two investigational immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers such as colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who hav…

This study tests whether adding a precise type of radiation (stereotactic radiosurgery) to standard drug therapy can better control brain metastases in people with melanoma or non-small cell lung cancer. About 180 participants with newly diagnosed, untreated brain metastases that…

This study is for adults with advanced solid tumors, including pancreatic, lung, bladder, and triple-negative breast cancer. It combines an immunotherapy drug (atezolizumab), an immune-boosting agent (BDB001), and targeted radiation to see if the trio can control or shrink tumors…

This early-phase study tests a new drug, MGC026, in 250 adults with advanced solid tumors that have not responded to other treatments. The goal is to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive the drug through an IV and are…

This study tests a new way to treat advanced melanoma by boosting a patient's own immune cells (TIL) with a molecule called CD40L. After standard treatments stop working, patients get chemotherapy followed by these enhanced cells and a short course of IL-2. The goal is to see if …

This study looks at how well the drug T-DXd works in adults with advanced HER2-positive cancers that have spread and no longer respond to other treatments. About 100 people will take part, and researchers will track whether tumors shrink and how long the benefit lasts. The goal i…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink or control the tumors. About 350 participants will take part in this early-phase trial.

This study tests a new drug, BMS-986340, alone or with other cancer drugs, in people with advanced solid tumors like lung, breast, or colon cancer. The goal is to find safe doses and check for side effects. About 949 adults whose cancer has worsened after standard treatment will …

This early-stage trial tests a new drug called GV20-0251 in people with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety in a small group of 10 participants with cancers like liver, lung, or pancreatic cancer. The s…

This study tests a type of internal radiation called high-dose-rate brachytherapy for people with liver tumors that cannot be surgically removed. The treatment uses a tiny radioactive source placed directly into the tumor to kill cancer cells while sparing nearby organs. Research…

This study tests a personalized cancer vaccine made from patients' own tumor cells. The goal is to train the immune system to fight metastatic cancers like melanoma, breast, lung, and colorectal cancer. Participants receive eight injections over 16 weeks. The study is for adults …

This early-phase trial tests an experimental oral drug, NST-628, in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway and have stopped responding to standard treatments. The study aims to find a safe dose and check for early signs of tumor s…

This study tests a drug called entrectinib, already approved for some lung cancers, in people with rare cancers that have a specific genetic change (ROS1 fusion). About 30 adults and children with these rare tumors will receive the drug. Researchers will measure if tumors shrink …

This study is testing a new combination of immune therapies for people with advanced melanoma that has not responded to standard treatments. The approach uses specially engineered immune cells (CAR T cells and CTLs) along with a dendritic cell vaccine to target and attack the can…

This study tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to standard therapies. It uses a patient's own immune cells taken from their tumor, grown in a lab, and given back to attack the cancer. About 98 adults will be randomly ass…

This early-phase study tests a treatment called RP1, a modified herpes virus, injected directly into melanoma tumors. The goal is to see if it can kill cancer cells and reduce the risk of the cancer spreading to nearby lymph nodes. The study involves 25 adults with thick or high-…

This study tests a new oral drug, IPN01194, in adults with advanced solid tumors (melanoma, colorectal, pancreatic, or head and neck cancers) that have not responded to standard treatments. The goal is to find the right dose and check if the drug is safe and can shrink tumors. Ab…

This study tests a new way to deliver radiation therapy for people with non-small cell lung cancer, melanoma, or kidney cancer that has started growing again in up to 5 spots. The approach uses a PET scan to find the most active parts of the tumor and delivers a higher radiation …

This early-stage trial tests a personalized cell therapy for children and young adults (up to age 21) with solid tumors that have come back or not responded to standard treatment. Doctors take the patient's own immune cells, modify them to recognize a protein called B7-H3 on tumo…

This study tests a treatment called electrochemotherapy for people with tumors in organs like the liver or pancreas that cannot be removed by surgery. The treatment uses short electric pulses to help chemotherapy drugs enter cancer cells more effectively. The goal is to shrink tu…

This study tests a new drug called NUC-7738, given by IV, for people with advanced solid tumors or lymphoma that have not responded to other treatments. The first part finds the safest dose and schedule, and the second part checks if the drug shrinks tumors when used alone or wit…

This early-stage study tests an experimental drug, REGN10597, alone or with another drug (cemiplimab) in people with advanced solid tumors like melanoma and kidney cancer. The main goals are to check safety, find the right dose, and see if the drugs shrink tumors. About 240 parti…

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or come back. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified to produce a protein (IL15) t…

This study tests an experimental drug called AZD6750, designed to help the immune system fight cancer. It is for adults with advanced solid tumors (like melanoma, lung, or breast cancer) that have spread. The trial will first find the safest dose, then test if it works alone or w…

This early-phase study tests a new drug, BI 3810944, in 69 adults with advanced solid tumors or melanoma who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug intravenously, usually every three w…

This study tests a new treatment for people with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, remove white blood cells, modify them in the lab to recognize and attack CD70, and then give t…

This study tests an experimental drug called TRK-950, alone or with another drug (nivolumab), in people with advanced solid tumors or melanoma that have not responded to standard treatments. The goal is to check safety, find the right dose, and see if the drug can shrink tumors. …

This early-stage study tests two drugs, ulixertinib and palbociclib, together in people with advanced solid tumors, including pancreatic cancer and certain melanomas. The main goal is to find the safest dose and check for side effects. About 45 adults whose cancer has not respond…

This study tests an experimental oral drug called Alintegimod combined with standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if the com…

This study tests whether adding the arthritis drug sarilumab to a three-drug immunotherapy cocktail can make treatment safer and more effective for people with advanced melanoma that cannot be removed by surgery. About 105 participants will receive the combination and be monitore…

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This study tests a new drug called HLX17 to see if it works like the approved cancer drug Keytruda. It is for people who have had surgery for lung cancer, melanoma, or kidney cancer. The study will compare how the drugs move through the body, their safety, and how well they work.…

This early-stage study tests an oral probiotic (R-5780) taken alongside a standard immunotherapy drug (PD-1 inhibitor) in adults with advanced solid tumors like melanoma. The main goal is to see if the combination is safe and tolerable. About 33 participants will be enrolled to a…

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The drug targets a protein called HER3 found on some cancer cells. About 740 adults with various cancers like lung, breast, or melanoma w…

This early-phase study tests a new drug, enzelkitug, alone or with standard immunotherapy, in adults with advanced solid tumors (e.g., lung, melanoma, breast, colon). The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 450 participants wil…

This study tests two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with rare cancers that have a specific BRAF V600 mutation. About 30 people with various cancer types will take the combination to see if it shrinks tumors or stops them from growing …

This study looks at whether giving radiation therapy to the lymph nodes, along with standard immunotherapy, can lower the chance of melanoma coming back in patients with high-risk features. About 168 adults with melanoma that has spread to a sentinel lymph node will receive radia…

This study looks at whether adding a prebiotic-rich diet to standard immunotherapy (ipilimumab and nivolumab) can improve the immune response in people with melanoma that can be surgically removed. About 35 adults with stage III or IV melanoma will follow the diet and take the dr…

This early-stage study tests an experimental drug called VSV-02 in 6 adults with advanced solid tumors (like melanoma, breast, or lung cancer) who have run out of standard treatments. The drug is given both into a vein and directly into the tumor to see if it can shrink or contro…

This study tests a new two-drug combination (fianlimab and cemiplimab) against an approved combination (relatlimab and nivolumab, sold as Opdualag) in people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to see if the new combo works better a…

This study tests whether adding the drug pembrolizumab to a treatment that uses a patient's own immune cells (called TIL therapy) can shrink tumors in people with advanced melanoma. About 170 adults aged 18 to 72 with skin melanoma that has spread will receive chemotherapy, then …

This study tests a new treatment for people with advanced melanoma that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) that target two proteins, NG2 and DLL3, found on melanoma cells. The goal is to see if th…

This study tests pembrolizumab, an immunotherapy that helps the immune system fight cancer, in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, returned, or not responded to treatment. The goal is to see if the drug can shrink …

This study tests a new drug called GI-101, either alone or with pembrolizumab or lenvatinib, in people with advanced solid tumors (cancers that have spread). The goal is to see if it is safe and works against the cancer. About 317 adults with certain cancers like lung, kidney, or…

This study tests a combination of two experimental drugs, HX009 and IN10018, with or without standard chemotherapy, in people with advanced solid tumors like bile duct cancer and melanoma that have not responded to prior treatments. The goal is to find the best dose and see if th…

This early-phase study tests a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors (like melanoma, lung, or colon cancer) that have a specific BRAF gene change and have stopped responding to standard treatments. The drug is given alone or combined w…

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This study tests whether adding a low-dose chemotherapy drug (cyclophosphamide) to an immunotherapy (pembrolizumab) can shrink tumors in people with advanced melanoma that no longer responds to standard immunotherapy. About 14 adults with stage III or IV melanoma will receive the…

This study tests whether giving immunotherapy before and after surgery helps people with advanced melanoma (stage III or IV). About 90 participants will receive treatment based on their tumor's biomarkers. The goal is to see if this approach leads to a major or complete response …

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This study is testing a new drug called DXC014 in people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check the drug's safety, find the best dose, and see if it can help shrink tumors. About 150 participants wi…

This study tests whether adding a fecal microbiota transplant called LND101 to standard immunotherapy can help keep advanced melanoma from growing or spreading. About 128 people with stage IV or unresectable melanoma will receive either immunotherapy alone or with LND101. The goa…

This early-phase trial tests a new treatment for people with advanced solid tumors (sarcoma, lung cancer, or melanoma) that have not responded to first-line therapy. The treatment involves taking a patient's own immune cells, modifying them in the lab to better recognize and atta…

This study is for people with stage III melanoma that has spread to just one lymph node. Doctors want to see if removing only that cancerous node can prevent the cancer from coming back in the same area, compared to removing more nodes. The trial will also track side effects like…

This study tests an experimental oral drug called NEO212 in people with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control the disease. About 134 adults will take part across t…

This early-stage trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for people with advanced uveal melanoma (an eye cancer) or certain sarcomas (soft tissue cancers). About 30 participants will have their tumor removed, immune…

This study offers continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were already benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to monitor long-term safety and side effects…

This study tests a combination of two drugs, enfortumab vedotin and pembrolizumab, in people with advanced melanoma that has worsened after standard treatments. The goal is to see if this combo can shrink tumors. About 60 adults with unresectable stage III or IV melanoma will tak…

This study is testing whether a combination of two drugs, axitinib and ipilimumab, can shrink tumors in people with advanced melanoma that has not responded to standard immunotherapy. About 25 adults with advanced or spreading melanoma will receive the treatment. The goal is to s…

This study tests whether combining a personalized cell therapy (lifileucel) with an immunotherapy drug (pembrolizumab) works better than the drug alone for people with advanced melanoma that cannot be removed by surgery or has spread. About 670 adults with untreated melanoma will…

This study tests whether a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) can shrink or stabilize melanoma tumors that have spread to the brain. About 60 adults with melanoma brain metastases will receive the drugs intravenously. The main goal is…

This study tests whether adding a drug called tarlatamab to standard radiation therapy is safe and effective for cancers that have a protein called DLL3, such as certain lung cancers, melanomas, and bladder cancers. About 30 adults with advanced or returning cancers will receive …

This study tests whether giving two doses of immunotherapy drugs (ipilimumab and nivolumab) before surgery can help shrink tumors in people with melanoma that has come back after previous treatment. About 25 adults with advanced but removable melanoma will receive the drugs, then…

This study tests a new treatment called T3011, given as a shot directly into tumors, for people with advanced or metastatic solid tumors (like melanoma or lung cancer). It is for adults whose cancer has worsened after standard treatments. The goal is to see if T3011 is safe and c…

This study tests a new experimental drug (PF-07799544) combined with another drug (PF-07799933) in adults with advanced solid tumors that have a specific gene change called BRAF V600. The goal is to see if the combination is safe and can shrink or control the cancer. Participants…

This study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or are not responding to standard treatments. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest …

This study looks at whether a special ultrasound using a contrast agent (Sonazoid) can find sentinel lymph nodes as well as the standard radioactive method in people with melanoma, breast cancer, or head & neck cancer. About 91 adults will take part for one day during their sched…

This study is testing a new radioactive tracer that targets a protein called LRRC15, found on many cancers like pancreatic, breast, lung, and brain tumors. The tracer is used with PET scans to see if it can better detect and stage these cancers compared to standard scans. The stu…

This study tests if a surgery called lymphovenous bypass, done before lymph node removal, can prevent lymphedema (arm swelling) in people with breast cancer or melanoma. About 252 participants will be followed to see if the bypass reduces the chance of swelling compared to standa…

This study tests whether receiving cancer treatment at home is preferred over going to a clinic for patients in the Florida Panhandle. About 27 adults with various cancers will get their usual therapy either at home or in clinic. The goal is to see if home treatment improves sati…

This study is testing a program called MyCarePulse and ASCENT to help cancer patients overcome food-related challenges. About 100 adults recently diagnosed with certain cancers will either receive the program or standard care. The goal is to see if the program improves food secur…

This study tests whether a virtual mind-body program called Integrative Medicine at Home (IM@Home) can reduce fatigue and improve quality of life for adults with head and neck, thoracic, gynecologic, or other cancers. Participants receive online sessions of practices like meditat…

This early-phase study tests whether fecal microbiota transplantation (FMT) can safely reduce severe diarrhea or colon inflammation caused by immune-checkpoint inhibitors in people with genitourinary and other cancers. About 40 participants will receive FMT and be monitored for s…

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps immune cells attack…

This study is testing a new tool that predicts whether immunotherapy will work for people with melanoma and other skin cancers. Researchers will collect tumor tissue, blood, and stool samples from 1,000 participants to see how accurate the predictions are. The goal is to help doc…

This study looks at how a standard immunotherapy drug (anti-PD1) changes the appearance and biology of atypical moles in people with advanced melanoma. About 30 participants with at least two atypical moles will be followed while receiving their normal treatment. The goal is to b…

This study aims to collect blood samples (liquid biopsies) from 2,500 people with cancer or at high risk for cancer, along with their medical information. The samples will be stored in a research bank for future studies to improve how we detect, monitor, and treat cancer. Partici…

This study enrolls up to 9,600 adults with various solid tumors (like breast, lung, or prostate cancer) to donate blood and leftover tissue samples. Researchers will use these samples to develop and improve tests that look for tiny bits of cancer DNA in the blood, which could hel…

This study is for people with advanced cancers who are taking targeted treatments for months or years. Researchers will interview 75 participants to understand their experiences and needs. The goal is to find better ways to support patients living with chronic cancer treatments.

This study is creating a huge collection of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand cancer causes, improve early detection, and develop person…

This study will follow 2,000 adults with newly diagnosed breast, colorectal, lung, melanoma, or lymphoma cancer who are starting chemotherapy or immunotherapy. Researchers want to see if using cannabis or cannabinoids helps with symptoms like pain, nausea, or fatigue, and whether…

This study screens up to 7,000 adults with cancers like melanoma, lung, or colorectal cancer to see if they qualify for experimental treatments developed by the National Cancer Institute's Surgery Branch. These treatments involve taking a patient's own immune cells, growing them …

This study aims to see if watching a video before genetic testing helps people with certain cancers better understand their hereditary cancer risk. About 1020 adults with breast, ovarian, pancreatic, prostate, colorectal, renal, melanoma, or sarcoma cancers will take part. Resear…

This study is testing a new educational tool designed for people with melanoma who also have an autoimmune disease (like rheumatoid arthritis or Crohn's disease). The tool helps patients understand immune checkpoint inhibitor drugs and their possible side effects. Researchers wil…

This study looks at whether giving young adults (ages 18-39) with cancer the option to choose how they report their symptoms and well-being leads to better data. About 400 participants will be randomly assigned to either a fixed set of questions or a choice of questions. The goal…

This study tracks how melanoma treatments (immunotherapy and targeted therapy) affect fertility in 80 men and women. Researchers measure hormone levels in women and sperm quality in men before, right after, and one year after treatment. The goal is to understand the impact on fer…

This study watches 50 people who already received replimune immunotherapy for cancers like melanoma or liver cancer. The goal is to see if any side effects show up years later. No new treatment is given—just regular checkups for 5 years.

This study is testing a mobile app called Vigilant to help monitor side effects in 100 people with skin cancer or melanoma who are starting a specific type of immunotherapy. Participants will use the app to report symptoms, and researchers will see if it helps catch serious side …

This study is testing whether an artificial intelligence tool can help match cancer patients with clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various cancers and use AI to analyze their tumor markers. The goal is to see if this app…

This study is collecting blood, tissue, and other samples from 7,000 people with different cancers to look for tiny bits of cancer DNA that may remain after treatment. The goal is to learn how to detect cancer early if it comes back. Participants' test results may help guide thei…

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of mu…

This study analyzes tumor tissue from up to 12,000 cancer patients to identify gene mutations. The goal is to match each patient with a clinical trial or therapy that targets their specific cancer type. Researchers will also build a database of mutations to improve future cancer …

This study tests whether a natural compound called urolithin A can improve the immune response in people with solid tumors (like lung cancer or melanoma) who are starting standard immunotherapy. About 45 adults will be randomly assigned to take either urolithin A or a placebo alo…

This study is testing a new way to analyze tumors using advanced lab techniques. Researchers want to see if this detailed testing can help doctors choose better treatments for people with high-risk blood cancers or solid tumors. About 300 patients aged one year and older will tak…

This study tests a digital tool called mySmartSkin to help melanoma survivors do better skin self-exams. About 385 people who had melanoma will use the app and report how thoroughly they check their skin. The goal is to see if the app helps catch new or returning melanomas earlie…

This study aims to see if a statewide educational campaign can help people in Oregon spot the early signs of melanoma, a serious skin cancer. Researchers will compare awareness and early detection rates in Oregon with neighboring states that did not receive the campaign. Up to 75…

This study collects blood and tumor samples from 1,000 people with melanoma and healthy volunteers. Researchers want to learn more about what causes melanoma and how tumors behave. The samples will be stored for future research that could lead to better ways to diagnose or treat …

This study aims to understand why some people and families are more likely to develop melanoma, a serious skin cancer. Researchers will collect medical history, blood or cheek cell samples, and skin samples from up to 3,000 volunteers aged 4 weeks or older who have a personal or …

This study collects leftover tissue and blood from 3,000 people with melanoma to look for genetic changes linked to the disease. The goal is to help doctors choose the best treatment for each patient. Participants must have a confirmed melanoma diagnosis and may donate samples fr…

This study looks at whether combining PET/CT scans with a special blood test (ctDNA) can help doctors predict which patients with advanced melanoma will respond to immunotherapy and who might have side effects. About 24 adults with stage III or IV melanoma will be followed for ab…

This study tracks 270 women under 40 who have had melanoma surgery and are now taking newer drugs (immunotherapy or targeted therapy) to prevent the cancer from coming back. Researchers want to see if these treatments harm the ovaries by measuring a hormone called AMH before and …

This study looks at the genetic information inside tumor samples from children and teens with melanoma or related skin growths. Researchers want to learn what makes these rare cancers different from adult melanomas. The study does not test any new treatments, but it may help doct…

This study looks at how the COVID-19 pandemic impacted the well-being and quality of life of people with melanoma. Researchers are surveying over 1,100 participants about their experiences, stress, finances, and social life during the pandemic. The goal is to understand what help…

This study follows 350 adults with stage III-IV melanoma for two years after diagnosis to understand their quality of life and mental health. Researchers will also test whether a type of talk therapy called cognitive behavioral therapy (CBT) can help reduce cancer-related distres…

This study looks at how electrochemotherapy—a treatment that uses electric pulses to help chemotherapy drugs enter tumor cells—changes the environment around melanoma skin tumors. Researchers will collect tissue samples from 150 adults with melanoma before and after treatment to …

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find cancer returning sooner than standard scans. Researchers will follow 100 people with various solid tumors to see if early detection leads to better treatment options. The goal is to improve how w…

This study looks at how effective first-line immunotherapy is for people with metastatic melanoma in Slovenia. Researchers will track treatment response and safety, and analyze blood, stool, and body fluids to find markers that predict who benefits most. The goal is to improve pe…